Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | CES1 | P23141 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26801 | 0.83 | ALDH1A1 (0.60) | ALDH1A1NPC1RAB9ACA12CA9 | |
| SCHEMBL2834701 | 0.79 | ALDH1A1 (0.48) | ALDH1A1NPC1RAB9ALMNAHTT | |
| SCHEMBL212272 | 0.77 | AKR1B1 (0.52) | ALDH1A1AKR1B1NPC1RAB9ACA12 | |
| SCHEMBL16935665 | 0.76 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9ACA12CA9 | |
| SCHEMBL968494 | 0.76 | ALDH1A1 (0.52) | ALDH1A1NPC1RAB9ACA12CA9 | |
| SCHEMBL186172 | 0.75 | MEP1B (0.50) | ALDH1A1AKR1B1NPC1RAB9ACA12 | |
| SCHEMBL7326431 | 0.74 | ALDH1A1 (0.50) | ALDH1A1NPC1RAB9AKMT2ATSHR | |
| SCHEMBL9476651 | 0.74 | AKR1B1 (0.48) | ALDH1A1AKR1B1NPC1RAB9ACA12 | |
| SCHEMBL7405544 | 0.74 | NPC1 (0.47) | ALDH1A1AKR1B1NPC1RAB9ACA12 | |
| SCHEMBL7301929 | 0.74 | LMNA (0.55) | ALDH1A1AKR1B1NPC1RAB9ACA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1416425-A | 1,5-bemzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2003-05-07 | — | — | CN | claimed |
| US-9663488-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals (NC), Inc. | 2015-12-10 | — | — | US | disclosed |
| EP-2948450-A1 | METALLOENZYME INHIBITOR COMPOUNDS | Viamet Pharmaceuticals, Inc. (US) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014117090-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2014-07-31 | — | — | WO | disclosed |
| CN-1416425-A | 1,5-bemzothiazepines and their use as hypolipidaemics | ASTRAZENECA AB (SE) | 2003-05-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353546-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | ALDH1A1 289/4885AKR1B1 951/4885NPC1 565/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.